What Enox Biopharma Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| David Itamar | Chief Financial Officer | Nov 04 | Open-market buy · P | −201,122 | $0.30 | −$60.3K | 324,361 |
| Avniel Amir | Chairman of the Board | Aug 12 | Open-market buy · P | +25,000 | $2.00 | +$50K | 25,000 |
| David Itamar | Chief Financial Officer | Aug 12 | Open-market buy · P | +25,000 | $2.00 | +$50K | 525,483 |
| David Itamar | Chief Financial Officer | Jul 15 | Open-market buy · P | +201,122 | $0.30 | +$60.3K | 500,483 |
| Av-Gay Yossef | President | Nov 02 | Open-market buy · P | +80,846 | $0.12 | +$10K | 5,355,846 |
Loading...
